Deutsch English Français

Contact

EP3038620

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3038620

EP3038620 - AGENT FOR THE TREATMENT AND PREVENTION OF CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 21.06.2019 Database last updated on 24.08.2024
Former	Examination is in progress Status updated on 05.10.2018
Most recent event Tooltip	21.06.2019	Application deemed to be withdrawn	published on 24.07.2019 [2019/30]
Applicant(s)	For all designated states Daiichi Sankyo Co., Ltd. 3-5-1, Nihonbashi-honcho Chuo-ku Tokyo 103-8426 / JP
	[2016/27]
Inventor(s)	01 / MERCURI, Michele 6 Allenby Lane Scotch Plains, New Jersey 07076 / US
	[2016/27]
Representative(s)	Nieuwenhuys, William Francis Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB
	[N/P]
Former [2016/27]	Nieuwenhuys, William Francis Marks & Clerk LLP 90 Long Acre London WC2E 9RA / GB
Application number, filing date	14766221.7	21.08.2014
	[2016/27]
	WO2014IB64006
Priority number, date	US201361871389P	29.08.2013 Original published format: US 201361871389 P
	[2016/27]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015028919
	Date:	05.03.2015
	Language:	EN
	[2015/09]
	Type:	A1 Application with search report
	No.:	EP3038620
	Date:	06.07.2016
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 05.03.2015 takes the place of the publication of the European patent application.
	[2016/27]
Search report(s)	International search report - published on:	EP	05.03.2015
Classification	IPC:	A61K31/429, A61K31/727, A61K45/06, A61K9/00, A61P35/00, A61P35/02, A61P35/04	[2016/27]
	CPC:	A61K31/444 (EP,US); A61K31/429 (EP,US); A61K31/727 (EP,US); A61K45/06 (EP,US); A61N5/10 (US); A61P35/00 (EP); (+) A61P35/02 (EP); A61P35/04 (EP); A61P43/00 (EP); A61P7/02 (EP) (-)
	C-Set:	A61K31/429, A61K2300/00 (EP,US); A61K31/727, A61K2300/00 (US,EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/27]
Title	German:	MITTEL ZUR BEHANDLUNG UND PRÄVENTION VON KREBS	[2016/27]
	English:	AGENT FOR THE TREATMENT AND PREVENTION OF CANCER	[2016/27]
	French:	AGENT POUR LE TRAITEMENT ET LA PRÉVENTION DU CANCER	[2016/27]
Entry into regional phase	09.02.2016	National basic fee paid
	09.02.2016	Designation fee(s) paid
	09.02.2016	Examination fee paid
Examination procedure	09.02.2016	Examination requested [2016/27]
	13.10.2016	Amendment by applicant (claims and/or description)
	08.10.2018	Despatch of a communication from the examining division (Time limit: M04)
	19.02.2019	Application deemed to be withdrawn, date of legal effect [2019/30]
	15.03.2019	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/30]
Fees paid	Renewal fee
	11.08.2016	Renewal fee patent year 03
	14.08.2017	Renewal fee patent year 04
	10.08.2018	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO2008033887 (NUVELO INC [US], et al) [X] 1-4,10-15,18-24,30-35,37,38 * page 3, line 18 - page 6, line 6 * * page 12, lines 16-24 * * page 21, line 17 - page 23, line 6 * * page 29, lines 12-19 *;
		[X]EP0404055 (MERRELL DOW PHARMA [US]) [X] 1,8-15,18,19,28-35,37 * page 2, lines 1-3, 25-30, 37-41 * * page 5, line 48 - page 6, line 28 *;
		[X]WO2010030983 (AUSPEX PHARMACEUTICALS INC [US], et al) [X] 1,8,9,12-14,18,19,28,29,32-34,36-38 * page 1, paragraphs 2-3 * * page 5, paragraph 14 * * page 18, paragraph 69 * * page 21, paragraphs 83-85 * * page 22, paragraph 87 - page 23 *;
		[I]WO2013014107 (AVENTIS PHARMA SA [FR], et al) [I] 1-38 * page 1, line 1 - page 3, line 5 * * page 5, lines 14-19 * * tables 3, 5-9 *;
		[I]EP2374456 (DAIICHI SANKYO CO LTD [JP]) [I] 1-38 * page 3, paragraphs 1-4 * * page 4, paragraphs 7-10 * * page 5, paragraph 13 * * page 7, paragraph 19 - page 8, paragraph 20 *;
		[I] - VAN DOORMAAL ET AL, "Development in anticoagulant therapy", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, (20071126), vol. 66, no. 2, ISSN 1040-8428, pages 145 - 154, XP022575956 [I] 1-38 * abstract * * page 147, column 2, paragraph 4 - page 149, column 1, paragraph 3 * * page 150, column 2, paragraphs 3-4 * * page 151, column 1, paragraph 4 * * page 151, column 2, paragraph 3 *
		[I] - Clinicaltrials.gov, "Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).", (20130604), Waybackmachine internet archive, URL: http://web.archive.org/web/20130604024806/http://clinicaltrials.gov/show/NCT00986154, (20141104), XP002733049 [I] 1-38 * the whole document *
		[XP] - HOKUSAI-VTE INVESTIGATORS ET AL, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.", THE NEW ENGLAND JOURNAL OF MEDICINE 10 OCT 2013, (20131010), vol. 369, no. 15, ISSN 1533-4406, pages 1406 - 1415, XP002733050 [XP] 1-38 * the whole document * * table 1 * DOI: http://dx.doi.org/10.1056/NEJMoa1306638
	by applicant	US7365205
		- T. FURUGOHRI ET AL., "D-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles", J. THROMBOSIS AND HAEMOSTASIS, (2008), vol. 6, doi:doi:10.1111/J.1538-7836.2008.03064.X, pages 1542 - 49, XP002659799 DOI: http://dx.doi.org/10.1111/J.1538-7836.2008.03064.X
		- S.M. BARGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
		- FIESSINGER ET AL., JAMA, (2005), vol. 293, page 681
		- BULLER ET AL., NEJM, (2007), vol. 357, page 1094

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p